Tailoring Biologic Therapies for Pediatric Severe Asthma: A Comprehensive Approach
Children · 27.01.2025 · 12 (2) · 140
DOI: 10.3390/children12020140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Children, online erschienen am 27.01.2025. Verfasst von Claudia María Chaverri Repáraz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hospital Universitario de Navarra (HUN), 31008 Pamplona, Spain. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Biologic therapies have revolutionized the management of severe asthma in pediatrics, offering targeted options for specific inflammatory pathways. This study aimed to review the current indications and availability of biologics approved for pediatric use as of January 2025 and to analyze the clinical experience of a tertiary center in managing this condition.
Methods
A comprehensive review of the biologics available for treating severe asthma in children was conducted, highlighting their indications and key characteristics. Additionally, a retrospective analysis was conducted on the experience of the Pediatric Severe Asthma Unit at the University Hospital of Navarra in utilizing these therapies between 2015 and 2025, with a focus on treatment distribution and reasons for switching biologics.
Results
As of January 2025, the biologics available for pediatric use include omalizumab, mepolizumab, dupilumab, tezepelumab, and benralizumab, each with specific indications and different administration profiles. At the analyzed center, the distribution of biologics was as follows: omalizumab (27%), mepolizumab (27%), dupilumab (37%), and tezepelumab (9%). At the same center, the biologic distribution 10 years earlier was 100% omalizumab. Therapy changes and switches were primarily related to clinical response, posology, and comorbidities.
Conclusions
This study emphasizes the importance of individualized management in pediatric severe asthma, based on continuous evaluation and appropriate biologic selection according to the clinical characteristics of each patient. It also highlights the need to develop specific guidelines for adjusting, switching, and discontinuing these therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Hospital Universitario de Navarra (HUN), 31008 Pamplona, Spain.
- Department of Pharmacy, Hospital Universitario de Navarra (HUN), 31009 Pamplona, Spain.
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
- Medicina, Facultad de Ciencias de la Salud, Universidad Pública de Navarra (UPNA), 31006 Pamplona, Spain.
ORCID-Profile: Esther Lacalle Fabo, María Erroz Ferrer, Natividad Viguria, Laura Moreno-Galarraga
Zitieren
APA
Chaverri Repáraz, C. M., Lacalle Fabo, E., Erroz Ferrer, M., Gimeno-Castillo, M., Castro-Garrido, I., Ibarzabal-Arregi, M., González Arza, N., Viguria, N., & Moreno-Galarraga, L. (2025). Tailoring Biologic Therapies for Pediatric Severe Asthma: A Comprehensive Approach. Children, 12(2), 140. https://doi.org/10.3390/children12020140
Vancouver
Chaverri Repáraz CM, Lacalle Fabo E, Erroz Ferrer M, Gimeno-Castillo M, Castro-Garrido I, Ibarzabal-Arregi M, et al. Tailoring Biologic Therapies for Pediatric Severe Asthma: A Comprehensive Approach. Children. 2025;12(2):140. doi:10.3390/children12020140
BibTeX
@article{ChaverriRepraz2025,
author = {Chaverri Repáraz, Claudia María and Lacalle Fabo, Esther and Erroz Ferrer, María and Gimeno-Castillo, María and Castro-Garrido, Isabel and Ibarzabal-Arregi, Miren and González Arza, Nerea and Viguria, Natividad and Moreno-Galarraga, Laura},
title = {Tailoring Biologic Therapies for Pediatric Severe Asthma: A Comprehensive Approach},
journal = {Children},
year = {2025},
volume = {12},
number = {2},
pages = {140},
doi = {10.3390/children12020140}
}
EUVIMED